Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04280718 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
A Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by argenx.
- Active
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
- 20
- Study locations
NCT04280718 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) that is active but no longer recruiting, run by argenx. The registered enrollment target is 229 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT04280718, a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod PH20 SC
Study Locations (20)
Florida
- Investigator site 0010072 - Boca Raton
- Investigator site 0010144 - Coral Springs
- Investigator site 0010023 - Jacksonville
- Investigator site 0010068 - Maitland
- Investigator site 0010059 - Miami
- Investigator site 0010006 - Tampa
California
- Investigator site 0010032 - Carlsbad
- Investigator site 10190 - Pomona
- Investigator site 0010160 - Rancho Mirage
- Investigator site 0010071 - San Francisco
Arizona
- Investigator site 0010013 - Phoenix
- Investigator site 0010055 - Scottsdale
Alabama
- Investigator site 0010065 - Birmingham
Colorado
- Investigator site 0010057 - Centennial
Iowa
- Investigator site 0010011 - Iowa City
Kansas
- Investigator site 0010015 - Fairway
Kentucky
- Investigator site 10147 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04280718
The ClinicalTrials.gov registry entry for NCT04280718 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod PH20 SC is the first listed.
NCT04280718 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04280718 about?
NCT04280718 is a clinical study titled "A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)". This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to exp...
What is the current status of trial NCT04280718?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2020-09-18. Estimated completion is 2027-04-30.
What conditions does trial NCT04280718 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
What interventions are being tested in trial NCT04280718?
The interventions under investigation include: Efgartigimod PH20 SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04280718?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04280718 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
COMPLETED · Phase 2
-
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.